ALLO
Price
$3.00
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
2 days until earnings call
CELC
Price
$15.25
Change
-$0.11 (-0.72%)
Updated
Nov 5, 04:00 PM (EDT)
2 days until earnings call
Ad is loading...

ALLO vs CELC

Header iconALLO vs CELC Comparison
Open Charts ALLO vs CELCBanner chart's image
Allogene Therapeutics
Price$3.00
Change-$0.00 (-0.00%)
Volume$3.16M
CapitalizationN/A
Celcuity
Price$15.25
Change-$0.11 (-0.72%)
Volume$9.24K
CapitalizationN/A
View a ticker or compare two or three
ALLO vs CELC Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALLO vs. CELC commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and CELC is a Buy.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (ALLO: $3.00 vs. CELC: $15.34)
Brand notoriety: ALLO and CELC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 162% vs. CELC: 58%
Market capitalization -- ALLO: $625.24M vs. CELC: $563.97M
ALLO [@Biotechnology] is valued at $625.24M. CELC’s [@Biotechnology] market capitalization is $563.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $488.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileCELC’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • CELC’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 7 TA indicator(s) are bullish while CELC’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 7 bullish, 2 bearish.
  • CELC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than CELC.

Price Growth

ALLO (@Biotechnology) experienced а +11.94% price change this week, while CELC (@Biotechnology) price change was -2.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.79%. For the same industry, the average monthly price growth was +15.00%, and the average quarterly price growth was +10.61%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

CELC is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($625M) has a higher market cap than CELC($568M). CELC YTD gains are higher at: 5.285 vs. ALLO (-6.542). CELC has higher annual earnings (EBITDA): -76.03M vs. ALLO (-256.56M). ALLO has more cash in the bank: 445M vs. CELC (283M). ALLO has less debt than CELC: ALLO (87M) vs CELC (96.5M). ALLO has higher revenues than CELC: ALLO (65K) vs CELC (0).
ALLOCELCALLO / CELC
Capitalization625M568M110%
EBITDA-256.56M-76.03M337%
Gain YTD-6.5425.285-124%
P/E RatioN/AN/A-
Revenue65K0-
Total Cash445M283M157%
Total Debt87M96.5M90%
FUNDAMENTALS RATINGS
ALLO vs CELC: Fundamental Ratings
ALLO
CELC
OUTLOOK RATING
1..100
7182
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5456
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (41) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for ALLO (97) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than ALLO’s over the last 12 months.

CELC's Profit vs Risk Rating (100) in the Miscellaneous Commercial Services industry is in the same range as ALLO (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (96) in the Biotechnology industry is in the same range as CELC (97) in the Miscellaneous Commercial Services industry. This means that ALLO’s stock grew similarly to CELC’s over the last 12 months.

ALLO's Price Growth Rating (54) in the Biotechnology industry is in the same range as CELC (56) in the Miscellaneous Commercial Services industry. This means that ALLO’s stock grew similarly to CELC’s over the last 12 months.

ALLO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that ALLO’s stock grew similarly to CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOCELC
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MACHX21.420.03
+0.14%
MoA Balanced Fund
YOVAX15.440.01
+0.06%
Yorktown Small-Cap A
IASRX22.18N/A
N/A
Delaware Ivy Asset Strategy Fund Cl R
FCIKX16.81-0.01
-0.06%
NYLI PineStone International Eq Inv Cl
MRFIX64.64-0.08
-0.12%
MFS Research I

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with NTLA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+10.29%
NTLA - ALLO
57%
Loosely correlated
+2.30%
FATE - ALLO
56%
Loosely correlated
+13.58%
CRSP - ALLO
55%
Loosely correlated
-0.28%
BEAM - ALLO
54%
Loosely correlated
+6.24%
PRME - ALLO
53%
Loosely correlated
-1.49%
More

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with QSI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+2.75%
QSI - CELC
42%
Loosely correlated
-1.35%
INZY - CELC
41%
Loosely correlated
+1.38%
PLRX - CELC
41%
Loosely correlated
-0.14%
SNDX - CELC
40%
Loosely correlated
-0.21%
ALLO - CELC
40%
Loosely correlated
+10.29%
More